5 news items
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
IMCR
31 May 24
Cutaneous melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
IMCR
29 May 24
melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin cancer
Analyst Expectations For Immunocore Hldgs's Future
IMCR
24 May 24
are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
Immunocore Hldgs's Financial Performance
Where Immunocore Hldgs Stands With Analysts
IMCR
29 Apr 24
, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
IMCR
11 Apr 24
States, of which the majority of its revenue comes from the United States.
A Deep Dive into Immunocore Hldgs's Financials
Market
- Prev
- 1
- Next